COLORADO SPRINGS, Colo., Nov. 6, 2013 /PRNewswire/ -- Endocan Corporation (NASDAQ OTC: ENDO), a U.S. Company specializing in cannabis and cannabinoid formulation-based health and wellness solutions, as of today begins trading with stock symbol "ENDO" rather than XCHC. FINRA announced yesterday the approval of the Company's new symbol, ENDO, effective with the start of trading today. This continues Endocan's rebranding effort in the rapidly expanding legal medical cannabis market. Endocan's rebranding began with internal changes, establishment of wholly-owned European subsidiaries Endocan BV and Endocan International Holdings BV, corporate name change in the United States, and launch of the updated Endocan.com website and Company social media platforms.
"We are pleased with the continued progress of Endocan Corporation and its brand promotion, including the corporate name change, website and product efforts, and now the successful change of trading symbol to 'ENDO'," stated Chad Johnson, COO and General Counsel, Endocan Corporation. "We look forward to continued enhancements to the new website, particularly its unique informational and patient sharing tool: the Patient Resource Center."
The website promotes the Endocan™ brand, now reflected by the Company's name and stock trading symbol, and will serve as a platform for new product releases designed for patients internationally. Of course, the website includes all the typical Endocan Corporate information including management biographies, contact information, and investor relations. Endocan Corporation is creating an enhanced international brand and image blending scientific expertise and a patient-oriented approach to enhance patient health with its proprietary cannabis and cannabinoid-based formulations. As well, the website has a pre-registration mechanism for its Patient Resource Center that is being developed to provide education and information on cannabis based medicine.
About Endocan Corporation
The brand name Endocan™ was chosen by the Board of Directors as a direct reference to the endocannabinoid system of the human body. The endocannabinoid system is a group of neuromodulatory compounds and their receptors that are involved in a variety of fundamental physiological processes including pain-sensation, immune function, stress, sleep, mood, appetite, and memory. Cannabinoids from plants, including those found in the Cannabis genus, as well as those autonomously produced within living biological systems, work together in the operation of the endocannabinoid system. The modulation of this system is the basis for cannabinoid-based medical treatments to assist patients to improve their health and well-being.
Endocan Corporation (FKA as The X-Change Corporation and FKA as XCHC) is currently developing new natural cannabinoid containing products based on innovative formulations to utilize the unique and potent benefits of the cannabis and hemp plants. Medicinal properties of cannabis and hemp have been known and applied for thousands of years. With the aid of scientific research, Endocan Corporation is translating such knowledge into development of effective cannabinoid formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands throughout the world. The Company's health and wellness, nutritional, and cosmetics lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.
Forward Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," "intend," "believe," "plan," "estimate," "expect," "project," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. The Company does not undertake any duty nor does it intend to update the results of these forward-looking statements.
CFO, Sr Vp of Business Development
SOURCE Endocan Corporation